Literature DB >> 23749984

Prevention of TGFβ induction attenuates angII-stimulated vascular biglycan and atherosclerosis in Ldlr-/- mice.

Tao Tang1, Patricia G Wilson1, Joel C Thompson1, Christina Nelson2, Meghan H Yoder2, Lisa R Tannock3.   

Abstract

Angiotensin II (angII) accelerates atherosclerosis, but the mechanisms are not fully understood. The aim of this study was to determine whether TGFβ is required for angII-induced atherosclerosis. Ldlr-null mice fed a normal chow diet were infused with angII or saline for 28 days. A single injection of TGFβ neutralizing antibody 1D11 (2 mg/kg) prevented angII-induction of TGFβ1 levels, and strikingly attenuated angII-induced accumulation of aortic biglycan content. To study atherosclerosis, mice were infused with angII or saline for 4 weeks, and then fed Western diet for a further 6 weeks. 1D11 had no effect on systolic blood pressure or plasma cholesterol; however, angII-infused mice that received 1D11 had reduced atherosclerotic lesion area by 30% (P < 0.05). Immunohistochemical analyses demonstrated that angII induced both lipid retention and accumulation of biglycan and perlecan which colocalized with apoB. 1D11 strikingly reduced the effect of angII on biglycan but not perlecan. 1D11 decreased total collagen content (P < 0.05) in the lesion area without changing plaque inflammation markers (CD68 and CD45). Thus, this study demonstrates that neutralization of TGFβ attenuated angII stimulation of biglycan accumulation and atherogenesis in mice, suggesting that TGFβ-mediated biglycan induction is one of the mechanisms underlying angII-promoted atherosclerosis.

Entities:  

Keywords:  TGFβ neutralizing antibody; angiotensin II; atherosclerosis initiation; biglycan-apoB colocalization; low density lipoprotein retention; proteoglycans; renin-angiotensin system

Mesh:

Substances:

Year:  2013        PMID: 23749984      PMCID: PMC3708375          DOI: 10.1194/jlr.P040139

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  54 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation.

Authors:  Karin Tran-Lundmark; Phan-Kiet Tran; Gabrielle Paulsson-Berne; Vincent Fridén; Raija Soininen; Karl Tryggvason; Thomas N Wight; Michael G Kinsella; Jan Borén; Ulf Hedin
Journal:  Circ Res       Date:  2008-07-03       Impact factor: 17.367

3.  Angiotensin-II-induced expression of laminin complex and laminin A-chain-related transcripts in vascular smooth muscle cells.

Authors:  S Regenass; T J Resink; F Kern; F R Bühler; A W Hahn
Journal:  J Vasc Res       Date:  1994 May-Jun       Impact factor: 1.934

4.  Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice.

Authors:  A Daugherty; L Cassis
Journal:  Ann N Y Acad Sci       Date:  1999-11-18       Impact factor: 5.691

5.  Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice.

Authors:  A Daugherty; M W Manning; L A Cassis
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

6.  Elevated systemic TGF-beta impairs aortic vasomotor function through activation of NADPH oxidase-driven superoxide production and leads to hypertension, myocardial remodeling, and increased plaque formation in apoE(-/-) mice.

Authors:  Anna Buday; Petra Orsy; Mária Godó; Miklós Mózes; Gábor Kökény; Zsombor Lacza; Akos Koller; Zoltán Ungvári; Marie-Luise Gross; Zoltán Benyó; Péter Hamar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-05-28       Impact factor: 4.733

7.  Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice.

Authors:  Sven Wassmann; Thomas Czech; Martin van Eickels; Ingrid Fleming; Michael Böhm; Georg Nickenig
Journal:  Circulation       Date:  2004-07-26       Impact factor: 29.690

8.  Augmentation of the renin-angiotensin system by hypercholesterolemia promotes vascular diseases.

Authors:  Alan Daugherty; Hong Lu; Debra L Rateri; Lisa A Cassis
Journal:  Future Lipidol       Date:  2008-12

9.  Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression.

Authors:  Esther Lutgens; Marion Gijbels; Marjan Smook; Peter Heeringa; Philip Gotwals; Victor E Koteliansky; Mat J A P Daemen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-06-01       Impact factor: 8.311

10.  TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice.

Authors:  Yu Wang; Hafid Ait-Oufella; Olivier Herbin; Philippe Bonnin; Bhama Ramkhelawon; Soraya Taleb; Jin Huang; Georges Offenstadt; Christophe Combadière; Laurent Rénia; Jason L Johnson; Pierre-Louis Tharaux; Alain Tedgui; Ziad Mallat
Journal:  J Clin Invest       Date:  2010-01-25       Impact factor: 14.808

View more
  10 in total

1.  Elevated circulating TGF-β is not the cause of increased atherosclerosis development in biglycan deficient mice.

Authors:  Joel C Thompson; Patricia G Wilson; Alex P Wyllie; Adrian K Wyllie; Lisa R Tannock
Journal:  Atherosclerosis       Date:  2017-11-10       Impact factor: 5.162

2.  Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF-β inhibition.

Authors:  Patricia G Wilson; Joel C Thompson; Meghan H Yoder; Richard Charnigo; Lisa R Tannock
Journal:  J Lipid Res       Date:  2017-09-14       Impact factor: 5.922

Review 3.  A role for proteoglycans in vascular disease.

Authors:  Thomas N Wight
Journal:  Matrix Biol       Date:  2018-02-27       Impact factor: 11.583

4.  A brief elevation of serum amyloid A is sufficient to increase atherosclerosis.

Authors:  Joel C Thompson; Colton Jayne; Jennifer Thompson; Patricia G Wilson; Meghan H Yoder; Nancy Webb; Lisa R Tannock
Journal:  J Lipid Res       Date:  2014-11-26       Impact factor: 5.922

5.  Increased atherosclerosis in mice with increased vascular biglycan content.

Authors:  Joel C Thompson; Tao Tang; Patricia G Wilson; Meghan H Yoder; Lisa R Tannock
Journal:  Atherosclerosis       Date:  2014-04-15       Impact factor: 5.162

6.  Biglycan deficiency: increased aortic aneurysm formation and lack of atheroprotection.

Authors:  Tao Tang; Joel C Thompson; Patricia G Wilson; Meghan H Yoder; Julia Müeller; Jens W Fischer; Kevin Jon Williams; Lisa R Tannock
Journal:  J Mol Cell Cardiol       Date:  2014-08-02       Impact factor: 5.000

Review 7.  Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets.

Authors:  Dipak P Ramji; Thomas S Davies
Journal:  Cytokine Growth Factor Rev       Date:  2015-05-12       Impact factor: 7.638

Review 8.  Angiotensin II, Hypercholesterolemia, and Vascular Smooth Muscle Cells: A Perfect Trio for Vascular Pathology.

Authors:  Amanda St Paul; Cali B Corbett; Rachael Okune; Michael V Autieri
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

9.  Biglycan Intensifies ALK5-Smad2/3 Signaling by TGF-β1 and Downregulates Syndecan-4 in Cultured Vascular Endothelial Cells.

Authors:  Takato Hara; Eiko Yoshida; Yasuhiro Shinkai; Chika Yamamoto; Yasuyuki Fujiwara; Yoshito Kumagai; Toshiyuki Kaji
Journal:  J Cell Biochem       Date:  2017-01-10       Impact factor: 4.429

Review 10.  TGFβ, smooth muscle cells and coronary artery disease: a review.

Authors:  Emma L Low; Andrew H Baker; Angela C Bradshaw
Journal:  Cell Signal       Date:  2018-09-15       Impact factor: 4.315

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.